Confirmed Summit Speakers, Chairs and Judges
–> Learn more & Register for the 2019 SharpBrains Virtual Summit: The Future of Brain Health
Thomas R. Insel, MD, Co-founder and President of Mindstrong Health and former Director of the National Institute of Mental Health (NIMH)
Dr. Insel is a psychiatrist, neuroscientist, and currently a co-founder and President of Mindstrong Health. From 2002–2015, Dr. Insel served as Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health (NIH) committed to research on mental disorders. Prior to serving as NIMH Director, Dr. lnsel was Professor of Psychiatry at Emory University where he was founding director of the Center for Behavioral Neuroscience in Atlanta. Most recently (2015 – 2017), he led the Mental Health Team at Verily (formerly Google Life Sciences) in South San Francisco, CA. Dr. Insel is a member of the National Academy of Medicine and has received numerous national and international awards including honorary degrees in the U.S. and Europe.
Dr. Deanna Belsky, Associate at Dolby Family Ventures
Deanna completed postdoctoral work at Stanford University, studying general molecular mechanisms in neurodegeneration, and she earned her PhD from Rockefeller University, studying ALS in Marc Tessier-Lavigne’s laboratory. Deanna has an accumulated 10 years of laboratory experience and is a recipient of the National Science Foundation Fellowship, Women in Science Grant, and Neuroscience Fellowship at Rockefeller University. Prior to joining the Dolby Family Ventures team, Deanna worked at a boutique biotech hedge fund and a life sciences consulting firm.
Dr. Srijan Sen, Professor of Depression and Neurosciences at University of Michigan
Srijan Sen is the Eisenberg Professor and Associate Chair for Research in the Department of Psychiatry at the University of Michigan. Dr. Sen leads the Intern Health Study, a longitudinal cohort study that assesses stress and mood in medical interns, enrolling over 3,000 participants from 80+ institutions each year. Work from the study has has advanced our understanding of biology of depression under stress and influenced medical education policies. His studies been published in leading journals and covered in the New York Times, Washington Post, Time Magazine and other media outlets. These papers have been cited over 120 times, on average, with two of the papers ranking among the Altmetrics top 100 articles of the year.
Jan Samzelius, Co-Founder & CEO
Jan has specialized in quantitative methods for 40 years and has invented the typing cadence technology central to NeuraMetrix. He has previously led a large number of analytical projects, ranging from measuring customer satisfaction to price elasticities to conjoint analyses. He has been the CEO of six companies (most of them startups), in several cases improving profits dramatically. His experience includes one turnaround and one successful exit. Jan holds a BSc in economics from the Stockholm School of Economics, graduating with honors and an MBA from Harvard Business School.
Dr. Tony Chang, Associate at Merck Ventures
Tony Chang, PhD, joined Ventures as an analyst in 2016 and transitioned into an Associate with the New Businesses team in April 2017. Prior to this, he was a technology commercialization officer at the University of Western Cape in South Africa where he was responsible for the development of several industry research collaborations and licensing deals. Previously, Tony was a consultant in the strategy practice of EY in Johannesburg. Tony received his PhD in medical biochemistry from the University of Cape Town and his MBA from Rotterdam School of Management, Erasmus University. Tony is based in Amsterdam.
Avery Bedows, Neurotechnology Specialist at Loup Ventures
Avery is obsessed with weaving technology, cognition, and human well-being into a braid. The lure of tech dates back to his first cellphone: in the two weeks before the phone shipped, he spent ~30 minutes a day feeling butterflies while looking at photos of the phone on the carrier’s website. His fascination with the brain began when he coauthored an introductory neuroscience book in high school, and evolved as he explored various aspects of cognitive science/cognitive neuroscience literature in his free time. His unwavering focus on, and convictions to facilitate, human well-being are just part of him.
Dr. Walter Greenleaf, Medical VR/ AR Expert at Stanford Virtual Human Interaction Lab
Walter Greenleaf is a research neuroscientist and medical product developer working at Stanford University. Walter is known internationally as an early pioneer in digital medicine and virtual reality (VR) technology. Walter is currently a Distinguished Visiting Scholar at Stanford University’s Virtual Human Interaction Lab, the Director of Technology Strategy at the University of Colorado National Mental Health Innovation Center, and Member of the Board of Directors for Brainstorm: The Stanford Laboratory for Brain Health Innovation and Entrepreneurship. In addition to his research at Stanford University, Walter is Senior Vice President of Strategic & Corporate Affairs to MindMaze and is VR/AR technology and neuroscience advisor to several early-stage digital health companies.
David B. Klein, Co-Founder & CEO of Click Therapeutics
David Benshoof Klein is a healthcare investor and entrepreneur with over 17 years life science industry experience; he has played key roles in founding, financing and operating more than 10 life science companies. In 2012, Mr.Klein co-founded Click Therapeutics which develops and commercializes software as medical treatments. He formerly served as Managing Director at Opus Point Partners, senior consultant to Pfizer, and strategic advisor to numerous publicly traded and privately held life science companies. Mr. Klein holds a B.A. from Brandeis University and has been a guest lecturer at Columbia University’s Biotechnology Program. A native New Yorker, Mr. Klein is an avid art enthusiast and is co-founder and owner of Klein Sun Gallery, America’s leading Chinese contemporary art gallery with locations in New York’s Chelsea art district and Beijing, China.
Ana Maiques, CEO of Neuroelectrics
Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to non-invasively monitor (EEG) and stimulate the brain (tCS-electrical stimulation) to help many patients in need. The company is now starting its regulatory path in the USA through a clinical trial in Boston. Ana Maiques was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain (2010) and received the EU Prize for Women Innovators from the European Commission EC in 2014 and one of the Most Inspiring Fifty Women in Europe. Neuroelectrics recently received the Best Start-up in Health 2015 by Wired UK magazine in London. She spends her time between Barcelona and Boston.
Keith Epstein, Healthcare Practice Leader at Blue Heron
Starting with Blue Heron in 2012, Keith has more than two decades of Washington-based investigative reporting and editing experience. His articles have appeared in major newspapers such as The Washington Post, the Miami Herald, and magazines including BusinessWeek, Congressional Quarterly, and CIO Insight. He has reported on regional and national political candidates, technology executives, and the pharmaceutical, health care, and insurance industries. He also was a leader at two independent nonprofit newsrooms, the Huffington Post Investigative Fund and the Center for Public Integrity. He has a BA from the University of Pennsylvania.
Dr. Karen Rommelfanger, Director of the Neuroethics Program at Emory University
Karen Rommelfanger is the Program Director of Emory University’s Neuroethics Program at the Center for Ethics and is an Assistant Professor in the Department of Neurology and in the Department of Psychiatry at Emory University. Dr. Rommelfanger received her PhD in Neuroscience from Emory University. She is also the Senior Associate Editor for the American Journal of Bioethics Neuroscience and board member of the International Neuroethics Society. She also serves as a member of the BRAIN Initiative’s Neuroethics Working Group and the advisory council to the director of NIH for BRAIN 2025. In her recent international work, she is co-chair of the International Brain Initiative’s Neuroethics Workgroup and is a member of the Global Futures Council on Neurotechnology for the World Economic Forum.
Dr. Anna Wexler, Assistant Professor at the Perelman School of Medicine at UPenn
Anna Wexler is an Assistant Professor in the Department of Medical Ethics and Health Policy at the Perelman School of Medicine at the University of Pennsylvania. She is the Principal Investigator of the Wexler Lab, which studies ethical, legal and social issues surrounding emerging technology, with a particular focus on do-it-yourself and direct-to-consumer medicine and science. She received her Ph.D. in 2017 from the HASTS (History, Anthropology, Science, Technology & Society) Program at MIT, where her dissertation centered on the DIY brain stimulation movement. Prior to her Ph.D., Anna worked as a freelance science/travel writer and documentary filmmaker. She co-directed and co-produced the feature documentary film Unorthodox (2013).
Jacqueline Studer, Senior VP and General Counsel of Akili Interactive Labs
Jackie has decades of experience providing legal strategy and support to large and emerging growth healthcare companies. Prior to joining Akili, she served as Corporate Vice President, General Counsel and Secretary at IDEXX Laboratories, where she led the legal, compliance and regulatory organizations. She held prior roles leading the legal, privacy and compliance organizations at Blue Health Intelligence, Allscripts Healthcare Solutions, and various leadership positions at GE Healthcare including as General Counsel of the GE Healthcare IT & Performance Solutions division. Studer holds a bachelor’s degree in management from Purdue University and a J.D. from Columbia University School of Law.
Dr. Clare Purvis, Fellow at Stanford Clinical Excellence Research Center
Dr. Clare Purvis completed her training in clinical psychology at Stanford University, VA Palo Alto Healthcare System, University of Wisconsin — Madison, and Palo Alto University (PGSP-Stanford Consortium). Clare’s graduate research focused on mental health technology, and she joined a mental health technology startup, Lantern, upon completing her doctorate. In that role, she created clinical interventions, conducted research, and applied evidence-based behavior science to inform user experience and design. She is fascinated by the intersection of technology and health, and believes in the potential for technological innovation to radically improve healthcare in the United States.
Louis Gagnon, CEO of Total Brain
Louis has 25 years of experience as a high-growth global digital businesses leader, most notably at Amazon’s subsidiary Audible where he served as Chief Product and Marketing Officer. He also was recently appointed Advisor to TPG Capital following a short CEO assignment to turn around portfolio company Ride.com. Other past notable roles include Chief Product & Marketing Officer at Yodle and Senior VP of Global Products at Monster Worldwide.
Dr. Gregory Rose, Director of the Center for Integrated Research in Cognitive and Neural Sciences at SIU Med
Dr. Rose (Ph.D. in Psychology, University of California at Irvine, 1980) is a faculty member with appointments in the Departments of Anatomy and Physiology at Southern Illinois University School of Medicine. His research area is Neuroscience, where he has long focused on understanding mechanisms of synaptic plasticity, learning, and age-related memory impairments. For the past several years he has been using functional magnetic resonance imaging techniques to examine changes in resting state functional connectivity following cognitive training in adolescents with learning disabilities. He has over 125 refereed publications in scientific journals as well as numerous invited book chapters, and over the years has received millions of dollars from national funding agencies to support his scientific studies. In mid-career he spent ten years in the pharmaceutical industry (Memory Pharmaceuticals and Bristol-Myers Squibb Co.) developing novel cognition enhancing drugs for the treatment of Alzheimer’s disease and schizophrenia.
Ariel Garten, Founder and Chief Evangelism Officer at InteraXon
Ariel Garten is the Founder and Chief Evangelism Officer of InteraXon, which creates thought controlled computing products and applications. Ariel has also researched at the Krembil Neuroscience Institute studying hippocampal neurogenesis, displayed work at the Art Gallery of Ontario, been head designer at a fashion label, and opened Toronto Fashion Week. Referred to as the “Brain Guru” by Now Magazine, CBC Radio and the Toronto Star, Ariel has also run a successful real estate business, spent time as the designer and owner of a Canadian fashion boutique, and is a practicing psychotherapist.
Dr. Margaret Morris, clinical psychologist, author of Left to Our Own Devices and former senior researcher at Intel
Margaret E. Morris is a clinical psychologist, researcher, and creator of technologies to support well-being. As a Senior Research Scientist at Intel from 2002 to 2016, she created and evaluated systems to promote emotional regulation, social connectedness and personal change. She has conducted User Experience research at Amazon and is an affiliate faculty member in the Department of Human-Centered Design and Engineering at the University of Washington, Seattle. In addition to creating new health technologies, Margaret examines how people appropriate existing tools to enhance health and relationships.
Rebecca Canter, Associate at the Dementia Discovery Fund (DDF)
Rebecca joined SV in July 2018 and works as an Associate for the Dementia Discovery Fund. Prior to joining SV, Rebecca was a Postdoctoral Scientist at Biogen in Cambridge, MA, conducting research on (neuro)inflammation in degenerative diseases like ALS, frontotemporal dementia, and Alzheimer’s disease. Her academic credentials include BA, Behavioral Biology, Johns Hopkins University; PhD, Brain and Cognitive Sciences, Massachusetts Institute of Technology. As outside interests Rebecca enjoys cycling, gardening, and travelling.
Dr. Peter Whitehouse, Professor of Neurology at Case Western Reserve University
Peter is a Professor of Neurology and former or current professor of Psychiatry, Psychology, Cognitive Science, Neuroscience, Bioethics, History, Nursing and Organizational Behavior at Case Western Reserve University, Professor of Medicine at the University of Toronto, and President of Intergenerational Schools International. He is also currently a strategic advisor in innovation at Baycrest Health Center. He received his undergraduate degree from Brown University and MD-PhD (Psychology) from The Johns Hopkins University (with positions at Harvard and Boston Universities), followed by a Fellowship in Neuroscience and Psychiatry and a faculty appointment at Hopkins.
Dr. Nir Grossman, Lecturer in the Division of Brain Sciences at Imperial College London
Nir is an assistant professor at Imperial College London and a founding fellow of the UK Dementia Research Institute. The long-term goal of his research is to develop neuromodulatory interventions for brain disorders by direct control of the aberrant neural activity. Nir received a BSc in physics from the Israeli Institute of Technology (Technion), an MSc in electromagnetic engineering from the Technical University of Hamburg-Harburg, and a PhD in neuroscience from Imperial College London. He then completed a postdoc training, as a Wellcome Trust Fellow, at the Massachusetts Institute of Technology (MIT) and Harvard University. Nir was recently received the Neuromodulation award by the Science magazine and PINS for describing how temporal interfering of electric fields can stimulate deep brain structures non-invasively.
Dr. Reza Zomorrodi, Project Scientist at University of Toronto’s Centre for Addiction and Mental Health (CAMH)
Dr. Reza Zomorrodi is a neuropsychology expert, with a penchant for computational neuroscienceis. He a Project Scientist at the Temerty Centre for Therapeutic Brain Intervention at CAMH. He holds a PhD in computational neuroscience from Laval University, and an MSc in atomic and molecular physics from IASBS-IRAN. Dr. Zomorrodi’s current research focuses on developing new signal processing techniques and applying non-invasive brain stimulation to study the role of disrupted brain network and enhance their functions in memory and cognition of patients with mental illness.
Yannick Roy, Co-founder of NeuroTechX
Yannick is spearheading NeuroTechX – the international neurotech community, as a cofounder and executive director. He is an electrical engineer with a background in computer science currently doing his PhD in visual neuroscience at University of Montreal. He’s obsessed about combining brain & tech. When he’s not engaging with other neurotech enthusiasts or managing neurotech projects, he’s usually in his lab working on his research. He also teaches computer science at ETS in Montreal.
Kito Rosetti, CEO at CTF MEG
Mr. Tosetti has many years of business experience in developing and managing ventures both in Canada and abroad. He has led multi-million dollar projects in the pharmaceutical, medical device and engineering industries. Previous CTF, he was the CEO of Zycor Labs, CEO of iCell Therapeutics and he co-founded and was the CEO of MIV Therapeutics Inc, which he grew from a start-up to a public company.
Álvaro Fernández, CEO and Editor-in-Chief of SharpBrains
Álvaro Fernández, a member of the World Economic Forum’s Council on the Future of Human Enhancement, runs SharpBrains, an independent market research firm tracking health and performance applications of brain science. Mr. Fernandez is the co-author of “The SharpBrains Guide to Brain Fitness: How to Optimize Brain Health and Performance at Any Age”, and the Editor-in-chief of SharpBrains’ market report on Pervasive Neurotechnology. Previously he worked in McKinsey & Company, Bertelsmann, Docent and Ashoka: Innovators for the Public, and has an MBA and MA in Education from Stanford University and a BA in Economics from Universidad de Deusto, in his native Spain.
Charlie Hartwell, Operating Partner at the Bridge Builders Collaborative
Charlie helps fund and support the visions of social entrepreneurs who have scalable business models for applications, practices, products, and tools that build bridges for mind-training. He is a Harvard Business School graduate who has led, founded, run and worked in organizations in 16 different industries. Previously Charlie was President of Ideas to Go, an innovation-consulting firm. His career has included Wall Street, corporate marketing stints at HJ Heinz and Pillsbury. In 1998, he formed the first for-profit expedition company in the US, helping launch the historic Bancroft Arnesen Expedition across Antarctica by polar explorers Ann Bancroft and Liv Arnesen.
Dr. Bob Bilder, Director of the UCLA Tennenbaum Center for the Biology of Creativity
Dr. Bob Bilder is the Director of the Tennenbaum Center for the Biology of Creativity in the Jane & Terry Semel Institute for Neuroscience and Human Behavior, and the Michael E. Tennenbaum Family Professor of Psychiatry & Biobehavioral Sciences and Chief of Medical Psychology — Neuropsychology at David Geffen School of Medicine. He has received many awards for his research contributions, served on diverse federal and international advisory boards, provided editorial service to many scholarly journals, and received multiple grants from the NIH, private foundations, and industry.
Kate Sharadin, Founder & CEO of eQuility
Kate is the founder and CEO of eQuility, developing a proprietary technology to treat CNS and Inflammatory disorders. Prior to founding eQuiity, she led the biomedical startup practice for the Invention Science Fund, incubating startup company projects in medical device and digital health. She is co-founder and board member of MEDX Accelerator, an Israeli medical device and digital health incubator in Tel Aviv. Previously she spent 23 years in the capital markets and investment banking, leading equity research and investment teams in medical technology/devices and led a strategic advisory practice for small private and public companies in the areas of medical device and regenerative medicine.
Nickolai Vysokov, Co-Founder & CEO of BrainPatch
Inspired by the beauty, complexity, and plasticity of the nerve cells, Nickolai dedicated his career to neuroscience. Nickolai completed his Ph.D. at Imperial College London focusing on neuronal development and then worked in industry on cell therapy for stroke patients. In 2017 together with his network of friends, he started an ambitious project to develop a commercial platform technology for using artificial intelligence (AI) in non-invasive brain stimulation.
Richard Hanbury, Founder & CEO of Sana Health
Richard Hanbury is founder and CEO of Sana Health, a neuromodulation platform for pain relief and deep relaxation, which he developed to eradicate his own life-threatening pain problem following a spinal-chord injury from a jeep crash near Sana in Yemen in 1992, its now his life’s mission to develop Sana to help others. Richard has an MBA (Healthcare) from the Wharton School, and DipLaw (College of Law London). He has spend 25 years developing the Sana technology from the original benchtop device to the current device undergoing clinical trials.
Dr. Hagit Alon, VP Scientific Affairs at Joy Ventures
Dr. Hagit Alon is passionate about biology, medicine and the technology related to them. She holds a PhD in computational biology from the faculty of medicine, Tel Aviv University, in collaboration with the National Institutes of Health (NIH). She also completed two masters degrees (in Molecular Biology from the Weizmann Institute of Science and in Computer Sciences, from New York University). Hagit established an innovative platform in the field of Amyotrophic Lateral Sclerosis (ALS). Her experience in leading a group of developers and maker skill set have secured her place in TOM (Tikkun Olam Makers) leadership team. She was part of the organizing team in various TOM events in Israel, San Francisco, San Diego and New York.
Kathleen Herath, Associate Vice President Health & Productivity at Nationwide Insurance
Kathleen Herath oversees the Health and Productivity strategy at Nationwide for the company’s 33,000 associates. She is responsible for the company’s integrated health and productivity program, which includes: health screenings, wellness programs, disability and disease management, health education, work-life resources and walking programs and occupational health clinics. The Health and Productivity program at Nationwide has received numerous national awards for the first four years including the 2009 IBI Health Innovation Award, the American Heart Association’s Platinum Fit-Friendly Employer award, the 2010 HUB magazine APEX award and the prestigious C. Everett Koop National Health Award.
Elan Tye, Investor at JAZZ Venture Partners
Elan is an investor with JAZZ Venture Partners focused on technologies that unlock human potential. Previously Elan has started and grown venture-backed startups as an operator and adviser across digital health, AI, and neurotech. Other experiences at the Boston Consulting Group and Monitor Deloitte. He received his BA from Tufts University and his MBA from the University of California, Berkeley.
Gilad Peleg-Lorberbaum, Chairman of Joy Ventures
Mr. Gilad Peleg-Lorberbaum is the Managing General Partner at Corundum Innovation, Co. Ltd, and serves as the Chairman at Joy Ventures. From 2008 up to late 2015 he was Chief Operating Officer at Rainbow Medical Ltd. Previously he led executive jobs at Glenrock Israel, NanoCyte Inc,
Marcel Legrand, Chief Revenue Officer of Total Brain
Marcel is a proven executive with a track record of achievement in innovation and positive fiscal results. Adept in all areas of strategic operations, sales management and market planning. Marcel is a Co-founder and operating partner of Vertical Knowledge LLC and previously served positions as partner at Blackfin Capital and Strategy & Corporate Development at Monster.
Dr. Lew Lim, CEO & Founder of VieLight
Lew Lim is an engineer with a passion for helping people. He is the co-inventor of several wearable photobiomodulation (PBM) / low level light therapy devices, and has been recognized for the development of the intranasal light therapy systems, particularly to address neurological issues. He is a Doctor of Natural Medicine with additional diplomas in Medical Neuroscience and Business and Accountancy. He obtained his degrees and diplomas from the University of California at Berkeley, University of Sheffield, Duke University, Quantum University and The Chartered Institute of Management Accountants, UK.
Debra Gilmore, Executive Director of The Arrowsmith Program
Debbie Gilmore is the new Executive Director of Arrowsmith Program, having been Arrowsmith’s representative in Australia and New Zealand for 18 months. Debbie first heard about the Arrowsmith Program when she was Head of Diverse Learning Needs at the Catholic Education Office, Sydney, Australia. Her work as a teacher, literacy adviser, assistant principal and principal helped her understand the need to ‘unlock’ the potential of students with learning difficulties, and her role as a mother of a son with such challenges gave her first hand experience of their struggles. Debbie holds a Masters of Education and various Graduate Certificates in Education.
Sydney Swaine-Simon, Co-founder of NeurotechX
Sydney is a Montreal native with an innate drive to grow the local innovation ecosystem. In 2012 Sydney became one of the co-founders of District 3, one of Quebec’s largest innovation centers. Having got a taste for innovation and technology, Sydney went on to co-found NeuroTechX, a non-profit organization which has built the largest network of neurotechnology enthusiasts. For fun, Sydney is a core member of the DEF CON Biohacking Village, as well as is a mentor for the Mozilla Open Leadership Program.
Mel Barsky, Director at Centre for Aging + Brain Health Innovation (CABHI)
Mel is responsible for .developing and identifying new commercial opportunities that will expand the continued Canadian and international growth of CABHI. Mel brings to CABHI more than 25 years of leadership experience in venture capital, healthcare IT, sales, marketing, operations, financial services and information technology. Mel has also served at INTERVENT Canada, Dynacare Medical Laboratories, Scotia Private Equity, and American Express. Mel holds an Honours Bachelor of Arts in Economics and Political Science from the University of Toronto, and a Master of Business Administration, Finance and International Business from Queen’s University.
Sylvain Piquet, COO of Peak
Sylvain is a seasoned international technology business leader, with a focus on operations, business development and digital marketing. Currently COO at Peak, a leading brain training app on mobile. Prior to Peak he was heading up Sales & Operations globally for the Paris based SSP Smart, and worked 7 years at Criteo, His specialties include building, structuring and leading international S&O teams; Mobile Advertising / Programmatic Ad Tech/ Retail, Travel and Classifieds eCommerce / Enterprise and Mid-Market Sales/ Cross-channel and cross-device Analytics and Attribution.
–> Learn more & Register for the 2019 SharpBrains Virtual Summit: The Future of Brain Health